Urine drug testing for pain management

Clinics in Laboratory Medicine

Volumn 32, Issue 3, 2012, Pages 379-390

  Magnani, Barbarajean ^a   Kwong, Tai ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Drug compliance; Opioids; Pain management; Urine drug testing

Indexed keywords

NARCOTIC ANALGESIC AGENT;

CONCENTRATION (PARAMETERS); DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG URINE LEVEL; HUMAN; IMMUNOASSAY; LONG TERM CARE; MANAGED CARE; PAIN; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; URINALYSIS;

ANALGESICS, OPIOID; HUMANS; IMMUNOASSAY; MEDICATION ADHERENCE; PAIN MANAGEMENT; PATIENT COMPLIANCE; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY; URINALYSIS;

EID: 84865610128     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2012.07.001     Document Type: Review

References (22)

1. The DAWN Report: highlights of the 2009 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits 2010, U.S.Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville (MD), Accessed June 15, 2012. http://oas.samhsa.gov/2k10/dawn034/edhighlights.htm.
2. National Vital Statistics System, Center for Disease Control and Prevention.
3. Trescot A.M., Helm S., Hansen H., et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008, 11:S5-S62.
4. 2011 prescription drug abuse prevention plan White House Office of National Drug Control Policy, Accessed June 15, 2012. http://www.whitehouse.gov/ondcp/prescription-drug-abuse.
5. Hammett-Stabler C.A., Webster L. Urine drug testing: augmenting pain management & enhancing patient care. PharmaCom Group 2008.
6. Chou R., Fanciullo G.J., Fine P.G., et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009, 10:113-130.
7. Michna E., Jamison R.N., Loc-Duyen, et al. Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings. Clin J Pain 2007, 23:173-179.
8. Couto J., Romney M., Leider H., et al. High rate of inappropriate drug use in the chronic pain population. Popul Health Manag 2009, 12:185-190.
9. Cone E.J., Caplan Y.H., Black D.L., et al. Urine drug testing of chronic pain patients: licit and illicit drug patterns. J Anal Toxicol 2008, 32:530-543.
10. Hammett-Stabler C., Magnani B.J. Supporting the pain service. Clinical toxicology testing 2012, 15-26. CAP Press, Northfield (IL). B.J. Magnani, M. Bissell, T. Kwong (Eds.).
11. Krasowski M.D., Pizon A.F., Siam M.G., et al. Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med 2009, 9:5.
12. Snyder M., Melanson S. Benzodiazepines. Clinical toxicology testing 2012, 132-139. CAP Press, Northfield (IL). B.J. Magnani, M. Bissell, T. Kwong (Eds.).
13. Notice changing the opiate testing cutoff concentrations [effective December 1, 1998] Federal Register, Accessed June 23, 2012. http://dwp.samhsa.gov/DrugTesting/Files_Drug_Testing/Notices_Docs_Resources/FR_Final/Federal%20Register%20Notice%20Changing%20the%20Opiate%20Testing%20Cutoff%20Concentrations.html.
14. Bottcher M., Beck O. Evaluation of buprenorphine CEDIA assay versus GC-MS and ELISA using urine samples from patients in substitution treatment. J Anal Toxicol 2005, 29:769-776.
15. Mikel C., Almazan P., West R., et al. LC-MS/MS extends the range of drug analysis in pain patients. Ther Drug Monit 2009, 31:746-748.
16. ElSohly H.N., ElSohly M.A., Standford D.F. Poppy seed ingestion of opiate urinalysis: a closer look. J Anal Toxicol 1990, 14:308-310.
17. Cone E., Caplan Y., Moser F., et al. Evidence that morphine is metabolized to hydromorphone but not to oxymorphone. J Anal Toxicol 2008, 32:319-323.
18. Oyler J., Cone E., Joseph R., et al. Identification of hydrocodone in human urine following controlled codeine administration. J Anal 2000, 24:530-535.
19. West R., West C., Crews B., et al. Anomalous observations of hydrocodone in patients on oxycodone. Clin Chim Acta 2011, 412:29-32.
20. West R., Crews B., Mikel C., et al. Anomalous observations of codeine in patients on morphine. Ther Drug Monit 2009, 31:776-778.
21. Reisfield G., Bertholf R., Barkin R., et al. Urine drug test interpretation: what do physicians know?. J Opioid Management 2007, 3:80-86.
22. Baron J., Griggs D., Nixon A., et al. The trazodone metabolite meta-chlorophenylpeperazine can cause false-positive urine amphetamine immunoassay results. J Anal Toxicol 2011, 35:363-368.